Tufts University

Tufts University is a moderately sized institution that integrates the characteristics of a research university with those of a liberal arts college, fostering an environment of curiosity and creativity. Established with a commitment to student-centered education, Tufts emphasizes the creation and application of knowledge across a diverse range of disciplines. The university offers various programs, including degrees in public health and health informatics through its School of Medicine, and is home to the Tufts Center for the Study of Drug Development, an independent nonprofit organization that enhances the quality and efficiency of pharmaceutical development. Tufts aims to provide transformational experiences for students and faculty in an inclusive and collaborative setting, encouraging innovative thinking and active engagement in addressing complex global challenges.

Michael Halassa

Director of Institutional Research at Department of Neuroscience

1 past transactions

Quanterix

Series D in 2016
Quanterix Corporation is a life sciences company focused on developing an ultra-sensitive digital immunoassay platform to advance precision health in diagnostics and research. Their proprietary technology, Simoa, enables the detection of protein biomarkers at very low concentrations in biological samples such as blood and serum, which are often undetectable using traditional methods. This high level of sensitivity allows for earlier disease detection, improved prognosis, and more precise treatment methods. Quanterix's platforms include bead-based and planar array systems designed to provide reliable and robust assay performance, addressing various unmet medical needs in clinical diagnostics, drug development, and life science research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.